Literature DB >> 35821343

Frequency, pattern, and associations of renal iron accumulation in sickle/β-thalassemia patients.

Antonella Meloni1,2, Luigi Barbuto3, Laura Pistoia1, Vincenzo Positano1,2, Stefania Renne4, Giuseppe Peritore5, Priscilla Fina6, Anna Spasiano7, Massimo Allò8, Giuseppe Messina9, Tommaso Casini10, Antonella Massa11, Luigia Romano3, Alessia Pepe12, Filippo Cademartiri13.   

Abstract

We evaluated frequency, pattern, and associations of renal iron accumulation in sickle/β-thalassemia. Thirty-three sickle/β-thalassemia patients (36.5 ± 14.7 years; 13 females), 14 homozygous sickle cell disease (SCD) patients, and 71 thalassemia major (TM) patients, enrolled in the E-MIOT Network, underwent magnetic resonance imaging. Iron overload (IO) was quantified by the T2* technique. Sickle/β-thalassemia patients had a significantly lower frequency of renal IO (T2* < 31 ms) than homozygous SCD patients (9.1% vs. 57.1%; P = 0.001), besides having similar hepatic, cardiac and pancreatic IO. Kidney T2* values were comparable between regularly transfused sickle/β-thalassemia and TM patients but were significantly lower in regularly transfused homozygous SCD patients than in the other two groups. In sickle/β-thalassemia patients, global renal T2* values were not associated with age, gender, splenectomy, and presence of regular transfusions or chelation. No correlation was detected between renal T2* values and serum ferritin levels or iron load in the other organs. Global renal T2* values were not associated with serum creatinine levels but showed a significant inverse correlation with serum lactate dehydrogenase (R =  - 0.709; P < 0.0001) and indirect bilirubin (R =  - 0.462; P = 0.012). Renal IO is not common in sickle/β-thalassemia patients, with a prevalence significantly lower compared to that of homozygous SCD patients, but with a similar underlying mechanism due to the chronic hemolysis.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Iron overload; Kidneys; Magnetic resonance imaging; Sickle/β-thalassemia

Mesh:

Substances:

Year:  2022        PMID: 35821343     DOI: 10.1007/s00277-022-04915-7

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   4.030


  16 in total

Review 1.  Transfusion management in sickle cell disease.

Authors:  Sam O Wanko; Marilyn J Telen
Journal:  Hematol Oncol Clin North Am       Date:  2005-10       Impact factor: 3.722

2.  Current trends in the diagnosis and management of haemoglobinopathies.

Authors:  D J Weatherall
Journal:  Scand J Clin Lab Invest       Date:  2007       Impact factor: 1.713

3.  The Sickle β-Thalassemia Phenotype.

Authors:  Adekunle D Adekile; Nagihan Akbulut; Asmaa F Azab; Sundus Al-Sharida; Diana Thomas
Journal:  J Pediatr Hematol Oncol       Date:  2017-07       Impact factor: 1.289

4.  Sickle cell/β-thalassemia: Comparison of Sβ0 and Sβ+ Brazilian patients followed at a single institution.

Authors:  Bruno Deltreggia Benites; Stephany Oliveira Bastos; Gabriel Baldanzi; Allan de Oliveira Dos Santos; Celso Dario Ramos; Fernando Ferreira Costa; Simone Cristina Olenscki Gilli; Sara Teresinha Olalla Saad
Journal:  Hematology       Date:  2016-05-28       Impact factor: 2.269

5.  Early markers of renal dysfunction in patients with sickle cell/beta-thalassemia.

Authors:  E Voskaridou; E Terpos; S Michail; E Hantzi; A Anagnostopoulos; A Margeli; D Simirloglou; D Loukopoulos; I Papassotiriou
Journal:  Kidney Int       Date:  2006-06       Impact factor: 10.612

6.  Identification of the haemoglobin scavenger receptor.

Authors:  M Kristiansen; J H Graversen; C Jacobsen; O Sonne; H J Hoffman; S K Law; S K Moestrup
Journal:  Nature       Date:  2001-01-11       Impact factor: 49.962

7.  Renal iron deposition by magnetic resonance imaging in pediatric β-thalassemia major patients: Relation to renal biomarkers, total body iron and chelation therapy.

Authors:  Mohsen Saleh ElAlfy; Nayera Hazaa Khalil Elsherif; Fatma Soliman Elsayed Ebeid; Eman Abdel Rahman Ismail; Khaled Aboulfotouh Ahmed; Yasser Wagih Darwish; Ahmed Samir Ibrahim; Islam Reda Farag Elghamry; Nermeen Adel Shokrey; Dunia Naser Alajeil
Journal:  Eur J Radiol       Date:  2018-04-09       Impact factor: 3.528

Review 8.  How we manage iron overload in sickle cell patients.

Authors:  Thomas D Coates; John C Wood
Journal:  Br J Haematol       Date:  2017-03-14       Impact factor: 6.998

Review 9.  Recent Advances in the Treatment of Sickle Cell Disease.

Authors:  Gabriel Salinas Cisneros; Swee L Thein
Journal:  Front Physiol       Date:  2020-05-20       Impact factor: 4.566

10.  Sickle cell disease: A distinction of two most frequent genotypes (HbSS and HbSC).

Authors:  Caroline Conceição da Guarda; Sètondji Cocou Modeste Alexandre Yahouédéhou; Rayra Pereira Santiago; Joelma Santana Dos Santos Neres; Camila Felix de Lima Fernandes; Milena Magalhães Aleluia; Camylla Vilas Boas Figueiredo; Luciana Magalhães Fiuza; Suellen Pinheiro Carvalho; Rodrigo Mota de Oliveira; Cleverson Alves Fonseca; Uche Samuel Ndidi; Valma Maria Lopes Nascimento; Larissa Carneiro Rocha; Marilda Souza Goncalves
Journal:  PLoS One       Date:  2020-01-29       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.